UBS lowered the firm’s price target on Boston Scientific (BSX) to $105 from $120 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Private Markets: Mind Robotics, Nexthop AI land $500M rounds
- Boston Scientific Targets China Stroke Market With New ENROUTE–WALLSTENT Registry
- Boston Scientific price target lowered to $94 from $102 at Citi
- IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Portfolio Diversification to Investors
- Boston Scientific Targets Drug-Resistant Motor Epilepsy With New Deep Brain Stimulation Trial